The complex relationship between female age and embryo euploidy.


Journal

Minerva obstetrics and gynecology
ISSN: 2724-6450
Titre abrégé: Minerva Obstet Gynecol
Pays: Italy
ID NLM: 101777346

Informations de publication

Date de publication:
02 2021
Historique:
pubmed: 12 12 2020
medline: 29 10 2021
entrez: 11 12 2020
Statut: ppublish

Résumé

Female age is the strongest predictor of embryo chromosomal abnormalities and has a nonlinear relationship with the blastocyst euploidy rate: with advancing age there is an acceleration in the reduction of blastocyst euploidy. Aneuploidy was found to significantly increase with maternal age from 30% in embryos from young women to 70% in women older than 40 years old. The association seems mainly due to chromosomal abnormalities occurring in the oocyte. We aimed to elaborate a model for the blastocyst euploid rate for patients undergoing in-vitro fertilization/intra cytoplasmic sperm injection (IVF/ICSI) cycles using advanced machine learning techniques. This was a retrospective analysis of IVF/ICSI cycles performed from 2014 to 2016. In total, data of 3879 blastocysts were collected for the analysis. Patients underwent PGT-Aneuploidy analysis (PGT-A) at the Center for Reproductive Medicine of European Hospital (Rome, Italy) have been included in the analysis. The method involved whole-genome amplification followed by array comparative genome hybridization. To model the rate of euploid blastocysts, the data were split into a train set (used to fit and calibrate the models) and a test set (used to assess models' predictive performance). Three different models were calibrated: a classical linear regression; a gradient boosted tree (GBT) machine learning model; a model belonging to the generalized additive models (GAM). The present study confirms that female age, which is the strongest predictor of embryo chromosomal abnormalities, and blastocyst euploidy rate have a nonlinear relationship, well depicted by the GBT and the GAM models. According to this model, the rate of reduction in the percentage of euploid blastocysts increases with age: the yearly relative variation is -10% at the age of 37 and -30% at the age of 45. Other factors including male age, female and male Body Mass Index, fertilization rate and ovarian reserve may only marginally impact on embryo euploidy rate. Female age is the strongest predictor of embryo chromosomal abnormalities and has a non-linear relationship with the blastocyst euploidy rate. Other factors related to both the male and female subjects may only minimally affect this outcome.

Sections du résumé

BACKGROUND
Female age is the strongest predictor of embryo chromosomal abnormalities and has a nonlinear relationship with the blastocyst euploidy rate: with advancing age there is an acceleration in the reduction of blastocyst euploidy. Aneuploidy was found to significantly increase with maternal age from 30% in embryos from young women to 70% in women older than 40 years old. The association seems mainly due to chromosomal abnormalities occurring in the oocyte. We aimed to elaborate a model for the blastocyst euploid rate for patients undergoing in-vitro fertilization/intra cytoplasmic sperm injection (IVF/ICSI) cycles using advanced machine learning techniques.
METHODS
This was a retrospective analysis of IVF/ICSI cycles performed from 2014 to 2016. In total, data of 3879 blastocysts were collected for the analysis. Patients underwent PGT-Aneuploidy analysis (PGT-A) at the Center for Reproductive Medicine of European Hospital (Rome, Italy) have been included in the analysis. The method involved whole-genome amplification followed by array comparative genome hybridization. To model the rate of euploid blastocysts, the data were split into a train set (used to fit and calibrate the models) and a test set (used to assess models' predictive performance). Three different models were calibrated: a classical linear regression; a gradient boosted tree (GBT) machine learning model; a model belonging to the generalized additive models (GAM).
RESULTS
The present study confirms that female age, which is the strongest predictor of embryo chromosomal abnormalities, and blastocyst euploidy rate have a nonlinear relationship, well depicted by the GBT and the GAM models. According to this model, the rate of reduction in the percentage of euploid blastocysts increases with age: the yearly relative variation is -10% at the age of 37 and -30% at the age of 45. Other factors including male age, female and male Body Mass Index, fertilization rate and ovarian reserve may only marginally impact on embryo euploidy rate.
CONCLUSIONS
Female age is the strongest predictor of embryo chromosomal abnormalities and has a non-linear relationship with the blastocyst euploidy rate. Other factors related to both the male and female subjects may only minimally affect this outcome.

Identifiants

pubmed: 33306288
pii: S0026-4784.20.04740-1
doi: 10.23736/S2724-606X.20.04740-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103-110

Auteurs

Antonio LA Marca (A)

Department of Medical and Surgical Sciences of the Mother, Children and Adults, Polyclinic of Modena, Modena, Italy - antonio.lamarca@unimore.it.

Martina Capuzzo (M)

Department of Medical and Surgical Sciences of the Mother, Children and Adults, Polyclinic of Modena, Modena, Italy.

Maria G Imbrogno (MG)

Department of Medical and Surgical Sciences of the Mother, Children and Adults, Polyclinic of Modena, Modena, Italy.

Valeria Donno (V)

Department of Medical and Surgical Sciences of the Mother, Children and Adults, Polyclinic of Modena, Modena, Italy.

Giorgio A Spedicato (GA)

UnipolSai Assicurazioni SpA, Bologna, Italy.

Sandro Sacchi (S)

Department of Medical and Surgical Sciences of the Mother, Children and Adults, Polyclinic of Modena, Modena, Italy.

Maria G Minasi (MG)

Center for Reproductive Medicine, Villa Mafalda, Rome, Italy.

Francesca Spinella (F)

GENOMA Group, Molecular Genetics Laboratories, Rome, Italy.

Pierfrancesco Greco (P)

Center for Reproductive Medicine, Villa Mafalda, Rome, Italy.

Francesco Fiorentino (F)

GENOMA Group, Molecular Genetics Laboratories, Rome, Italy.

Ermanno Greco (E)

Center for Reproductive Medicine, Villa Mafalda, Rome, Italy.
UniCamillus, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH